4275 Executive Square
La Jolla, CA 92037
619 592 9775
Full Time Employees: 21
|Mr. Kevin R. Lind||Pres, CEO, Sec. & Director||875.13k||N/A||1976|
|Ms. Brandi L. Roberts CPA, M.B.A.||Chief Financial Officer||568.57k||N/A||1974|
|Mr. Chadwick J. Orevillo MPH||VP & Head of Operations||N/A||N/A||N/A|
|Megan E. Knight||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Steven W. Spector J.D.||Head of Bus. Devel. & Gen. Counsel||N/A||N/A||1965|
|Dr. Anne M. Danks||VP & Head of Preclinical Devel.||N/A||N/A||N/A|
|Dr. Jodi Parsons||VP & Head of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Randall E. Kaye M.D.||Chief Medical Officer||N/A||N/A||1962|
|Mr. Gus Cardenas||VP & Head of Quality Assurance||N/A||N/A||N/A|
|Dr. Marco Peters Ph.D.||VP & Head of Translational Science||N/A||N/A||N/A|
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Longboard Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.